Tissue | Expression Dynamics | Abbreviation |
Cervix | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Cervix/EZH2_pca_on_diff_genes.png) | CC: Cervix cancer |
HSIL_HPV: HPV-infected high-grade squamous intraepithelial lesions |
N_HPV: HPV-infected normal cervix |
Endometrium | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Endometrium/EZH2_pca_on_diff_genes.png) | AEH: Atypical endometrial hyperplasia |
EEC: Endometrioid Cancer |
Esophagus | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Esophagus/EZH2_pca_on_diff_genes.png) | ESCC: Esophageal squamous cell carcinoma |
HGIN: High-grade intraepithelial neoplasias |
LGIN: Low-grade intraepithelial neoplasias |
Liver | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Liver/EZH2_pca_on_diff_genes.png) | HCC: Hepatocellular carcinoma |
NAFLD: Non-alcoholic fatty liver disease |
Lung | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Lung/EZH2_pca_on_diff_genes.png) | AAH: Atypical adenomatous hyperplasia |
AIS: Adenocarcinoma in situ |
IAC: Invasive lung adenocarcinoma |
MIA: Minimally invasive adenocarcinoma |
Oral Cavity | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/OralCavity/EZH2_pca_on_diff_genes.png) | EOLP: Erosive Oral lichen planus |
LP: leukoplakia |
NEOLP: Non-erosive oral lichen planus |
OSCC: Oral squamous cell carcinoma |
Thyroid | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Thyroid/EZH2_pca_on_diff_genes.png) | ATC: Anaplastic thyroid cancer |
HT: Hashimoto's thyroiditis |
PTC: Papillary thyroid cancer |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:00085446 | Cervix | CC | epidermis development | 83/2311 | 324/18723 | 3.91e-11 | 8.54e-09 | 83 |
GO:000697910 | Cervix | CC | response to oxidative stress | 102/2311 | 446/18723 | 2.99e-10 | 4.36e-08 | 102 |
GO:003367410 | Cervix | CC | positive regulation of kinase activity | 101/2311 | 467/18723 | 8.66e-09 | 7.22e-07 | 101 |
GO:00430877 | Cervix | CC | regulation of GTPase activity | 79/2311 | 348/18723 | 4.21e-08 | 2.60e-06 | 79 |
GO:00099137 | Cervix | CC | epidermal cell differentiation | 53/2311 | 202/18723 | 5.48e-08 | 3.25e-06 | 53 |
GO:00458608 | Cervix | CC | positive regulation of protein kinase activity | 85/2311 | 386/18723 | 5.61e-08 | 3.29e-06 | 85 |
GO:000030210 | Cervix | CC | response to reactive oxygen species | 56/2311 | 222/18723 | 1.00e-07 | 5.25e-06 | 56 |
GO:006219710 | Cervix | CC | cellular response to chemical stress | 76/2311 | 337/18723 | 1.01e-07 | 5.25e-06 | 76 |
GO:00447725 | Cervix | CC | mitotic cell cycle phase transition | 89/2311 | 424/18723 | 2.70e-07 | 1.12e-05 | 89 |
GO:00163587 | Cervix | CC | dendrite development | 58/2311 | 243/18723 | 4.52e-07 | 1.76e-05 | 58 |
GO:004254210 | Cervix | CC | response to hydrogen peroxide | 40/2311 | 146/18723 | 6.79e-07 | 2.46e-05 | 40 |
GO:00305229 | Cervix | CC | intracellular receptor signaling pathway | 60/2311 | 265/18723 | 1.89e-06 | 5.97e-05 | 60 |
GO:004887210 | Cervix | CC | homeostasis of number of cells | 61/2311 | 272/18723 | 2.17e-06 | 6.55e-05 | 61 |
GO:00719007 | Cervix | CC | regulation of protein serine/threonine kinase activity | 75/2311 | 359/18723 | 2.76e-06 | 8.02e-05 | 75 |
GO:00485118 | Cervix | CC | rhythmic process | 65/2311 | 298/18723 | 2.79e-06 | 8.04e-05 | 65 |
GO:003459910 | Cervix | CC | cellular response to oxidative stress | 63/2311 | 288/18723 | 3.58e-06 | 9.50e-05 | 63 |
GO:00109757 | Cervix | CC | regulation of neuron projection development | 88/2311 | 445/18723 | 4.26e-06 | 1.09e-04 | 88 |
GO:00510904 | Cervix | CC | regulation of DNA-binding transcription factor activity | 87/2311 | 440/18723 | 4.85e-06 | 1.22e-04 | 87 |
GO:00456822 | Cervix | CC | regulation of epidermis development | 22/2311 | 65/18723 | 5.56e-06 | 1.38e-04 | 22 |
GO:20000453 | Cervix | CC | regulation of G1/S transition of mitotic cell cycle | 37/2311 | 142/18723 | 6.33e-06 | 1.53e-04 | 37 |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
EZH2 | SNV | Missense_Mutation | | c.2168N>T | p.Thr723Ile | p.T723I | Q15910 | protein_coding | deleterious(0.02) | probably_damaging(0.997) | TCGA-A2-A0YE-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unspecific | Taxotere | SD |
EZH2 | SNV | Missense_Mutation | novel | c.1475N>A | p.Thr492Asn | p.T492N | Q15910 | protein_coding | tolerated(0.27) | probably_damaging(0.997) | TCGA-E9-A1N5-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | doxorubicin | SD |
EZH2 | insertion | In_Frame_Ins | novel | c.940_941insGAACAAGAATATTAACAAAAATAAAACGAACATTAG | p.Lys314delinsArgThrArgIleLeuThrLysIleLysArgThrLeuGlu | p.K314delinsRTRILTKIKRTLE | Q15910 | protein_coding | | | TCGA-AO-A128-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | doxorubicin | SD |
EZH2 | SNV | Missense_Mutation | novel | c.1903G>T | p.Asp635Tyr | p.D635Y | Q15910 | protein_coding | deleterious(0.05) | probably_damaging(0.94) | TCGA-2W-A8YY-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
EZH2 | SNV | Missense_Mutation | | c.1090N>T | p.Pro364Ser | p.P364S | Q15910 | protein_coding | tolerated(0.48) | benign(0.178) | TCGA-C5-A1M9-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | PD |
EZH2 | SNV | Missense_Mutation | | c.877N>C | p.Asp293His | p.D293H | Q15910 | protein_coding | deleterious(0) | probably_damaging(0.999) | TCGA-EX-A69L-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD |
EZH2 | SNV | Missense_Mutation | | c.2084C>T | p.Ser695Leu | p.S695L | Q15910 | protein_coding | deleterious(0.05) | probably_damaging(0.994) | TCGA-IR-A3LA-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
EZH2 | SNV | Missense_Mutation | | c.1760C>T | p.Pro587Leu | p.P587L | Q15910 | protein_coding | deleterious(0) | probably_damaging(0.999) | TCGA-A6-2679-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
EZH2 | SNV | Missense_Mutation | | c.926N>G | p.Asn309Ser | p.N309S | Q15910 | protein_coding | tolerated(0.17) | possibly_damaging(0.881) | TCGA-A6-3809-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
EZH2 | SNV | Missense_Mutation | | c.451N>C | p.Lys151Gln | p.K151Q | Q15910 | protein_coding | deleterious(0.01) | possibly_damaging(0.727) | TCGA-A6-6141-01 | Colorectum | colon adenocarcinoma | Male | <65 | I/II | Chemotherapy | 5-fu | SD |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
2146 | EZH2 | CLINICALLY ACTIONABLE, ENZYME, METHYL TRANSFERASE, NUCLEAR HORMONE RECEPTOR, TRANSCRIPTION FACTOR | | Vorinostat | VORINOSTAT | 25605023 |
2146 | EZH2 | CLINICALLY ACTIONABLE, ENZYME, METHYL TRANSFERASE, NUCLEAR HORMONE RECEPTOR, TRANSCRIPTION FACTOR | | PMID28394193-Compound-19 | | |
2146 | EZH2 | CLINICALLY ACTIONABLE, ENZYME, METHYL TRANSFERASE, NUCLEAR HORMONE RECEPTOR, TRANSCRIPTION FACTOR | inhibitor | 363894175 | | |
2146 | EZH2 | CLINICALLY ACTIONABLE, ENZYME, METHYL TRANSFERASE, NUCLEAR HORMONE RECEPTOR, TRANSCRIPTION FACTOR | | PMID28394193-Compound-13 | | |
2146 | EZH2 | CLINICALLY ACTIONABLE, ENZYME, METHYL TRANSFERASE, NUCLEAR HORMONE RECEPTOR, TRANSCRIPTION FACTOR | | PMID28394193-Compound-25 | | |
2146 | EZH2 | CLINICALLY ACTIONABLE, ENZYME, METHYL TRANSFERASE, NUCLEAR HORMONE RECEPTOR, TRANSCRIPTION FACTOR | | PMID28394193-Compound-50 | | |
2146 | EZH2 | CLINICALLY ACTIONABLE, ENZYME, METHYL TRANSFERASE, NUCLEAR HORMONE RECEPTOR, TRANSCRIPTION FACTOR | | PMID28394193-Compound-53 | | |
2146 | EZH2 | CLINICALLY ACTIONABLE, ENZYME, METHYL TRANSFERASE, NUCLEAR HORMONE RECEPTOR, TRANSCRIPTION FACTOR | | PMID28394193-Compound-30 | | |
2146 | EZH2 | CLINICALLY ACTIONABLE, ENZYME, METHYL TRANSFERASE, NUCLEAR HORMONE RECEPTOR, TRANSCRIPTION FACTOR | | EPZ-6438 | TAZEMETOSTAT | |
2146 | EZH2 | CLINICALLY ACTIONABLE, ENZYME, METHYL TRANSFERASE, NUCLEAR HORMONE RECEPTOR, TRANSCRIPTION FACTOR | | PMID28394193-Compound-57 | | |